

Collecting and Banking Ewing Sarcoma Specimens (AEWS07B1)

IRB# 2008-036

Principal Investigator: Carla Golden, MD

Synopsis:

The current treatment for Ewing sarcoma involves high dose chemotherapy along with surgery and/or radiation therapy. These treatments are associated with significant short- and long-term morbidities. The main prognostic factor that is currently in use is whether a patient has metastatic disease at presentation. Using this factor, the cure rate for localized disease is only between 60-80%, and the cure rate for patients with metastatic disease is less than 35%. Attempts to improve outcome are likely to involve escalations in dose-intensity and the introduction of new agents into current therapeutic protocols. Improvements in outcome prediction will help to identify those patients who are unlikely to benefit from current regimens. Improvements in understanding the biologic basis for Ewing sarcoma are likely to identify molecular pathways that may be targeted with therapeutic efficacy. Advances in diagnostic, prognostic, and therapeutic approaches to this disease require clinically-annotated biologic materials from patients with Ewing sarcoma. The purpose of this study is to collect patient-derived materials, including associated demographic and clinical data, to provide a repository for long-term storage of these materials, and to make these materials available to qualified researchers to understand the biology of Ewing sarcoma and correlate these results with the patient's clinical data. In this way we hope to improve the understanding of Ewing sarcoma, and in doing so, improve the outcome of patients with this disease.